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Abstract 
 
Excessive proliferation of human pulmonary artery smooth muscle cells (HPASMC) is one of 
the major factors that trigger vascular remodeling in hypoxia-induced pulmonary 
hypertension. Several studies have implicated that hypoxia inhibits the tumour suppressor 
p21 (CDKN1A). However, the precise mechanism is unknown. 
The mouse model of hypoxia-induced PH and in vitro experiments were used to 
assess the impact of microRNAs (miRNAs) on the expression of CDKN1A. In these 
experiments, the miRNA family miR-130 was identified to regulate the expression of 
CDKN1A. Transfection of HPASMC with miR-130 decreased the expression of CDKN1A 
and, in turn, significantly increased smooth muscle proliferation. Conversely, inhibition of 
miR-130 by anti-miRs and seed blockers increased the expression of CDKN1A. Reporter 
gene analysis proved a direct miR-130 – CDKN1A target interaction. Exposure of HPASMC 
to hypoxia was found to induce the expression of miR-130 with concomitant decrease of 
CDKN1A. These findings were confirmed in the mouse model of hypoxia-induced pulmonary 
hypertension showing that the use of seed blockers against miR-130 restored the expression 
of CDKN1A.  
These data suggest that miRNA family miR-130 plays an important role in the 
repression of CDKN1A by hypoxia. miR-130 enhances hypoxia-induced smooth muscle 
proliferation and might be involved in the development of right ventricular hypertrophy and 
vascular remodeling in pulmonary hypertension.  
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1. Introduction 
 
Pulmonary hypertension (PH), a severe condition leading to right heart failure, is 
characterized by vasoconstriction, microthrombotic events and remodeling of the small 
pulmonary arteries 1. Of these changes, vascular remodeling due to the proliferation of 
endothelial and vascular smooth muscle cells is arguably the most important alteration and, 
to date, is not directly targeted by treatment. Several mechanisms have been identified that 
trigger the development of a pro-proliferative phenotype of these vessel cells, in particular 
disrupted signaling of the bone morphogenetic protein receptor type II (BMPR2) 2, 3.  
 
Recently, activation of the tumor suppressor p53 in lungs by Nutlin-3a has been shown to 
prevent and reverse pulmonary arterial remodeling in experimental models for PH 4. The 
pro-senescent and anti-proliferative effects of Nutlin-3a were abolished in p21-deficient 
animals, in which the gene for the cell cycle dependent kinase inhibitor (CDKN)1A (alias 
p21) was abolished. These genetically modified animals developed significantly more severe 
pulmonary hypertension than wild-type controls when exposed to chronic hypoxia, which is 
one of the best-established pathogenic factors triggering pulmonary arterial vasoconstriction 
and vascular remodeling in an experimental setting 5. CDKN1A thus appears to be of major 
importance for mediating the remodeling of pulmonary arteries in response to hypoxia. The 
mechanisms resulting in altered expression of CDKN1A, however, are unknown. For 
example, it remains unraveled whether the dysregulation of these signaling events is only a 
downstream consequence of changes in the expression of BMPR2 or whether other factors 
might directly target CDKN1A. Such factors might involve the action of microRNAs 
(miRNAs), i.e. small, non-coding RNAs that bind to the mRNA of a target gene and, by 
mRNA degradation or inhibition of translation, result in gene silencing. It is suggested that 
more than 60% of the human genome is regulated by miRNAs 6. In the context of PH, 
miRNAs have emerged as important pathogenetic factors 7, 8, 9 that mediate intracellular 
signaling events 10 and act as post-transcriptional regulators for the expression of BMPR2 11, 
12, 13, 14. 
 
In the current study, following a screening for miRNAs that potentially bind CDKN1A, we 
focused on members of the miRNA family miR-130 (including miR-130a/b and miR-301a/b) 
and addressed the effects of these miRNAs on the expression of CDKN1A and, in turn, on 
the proliferation of human pulmonary artery smooth muscle cells (HPASMC). Finally, we 
tested the hypothesis whether the use of anti-miRs or locked nucleic acid (LNA) seed 
blockers directed against miR-130 results in increased expression levels of CDKN1A in vitro 
and in vivo.     
 
2. Material and Methods 
 
2.1. Animal experiments 
Male mice (C57BL/6) were bred at the Institute for Veterinary Physiology, University of 
Zurich. The animals were randomly grouped in a normoxic control group (7 mice) and in a 
hypoxic group (8 mice, 10% O2). Hypoxic condition was provided in a chamber connected to 
a gas mixer (Ruskinn Technology Limited, Bridgend, UK). Mice were assessed daily for 
activity and well-being. Food and water was provided ad libitum. Mice employed during initial 
screening for expression of miRNAs and CDKN1A (Figure 1 and Figure A.3) were exposed 
to 10% O2 for 3 weeks, additional kinetic experiments were performed in 3 mice after 2 
weeks. At day 21 mice were anaesthetized with 5% isoflurane in oxygen and subsequently 
euthanized by CO2 inhalation. Mice used for treatment studies (Figure 6) were exposed to 
hypoxia for 35 days. LNA seed blockers (2.5mg/kg bodyweight) were injected 
intraperitoneally twice at day 21 and day 28. At day 35 mice were anaesthetized with 5% 
isoflurane in oxygen and subsequently euthanized by CO2 inhalation. Lungs and hearts 
were collected for further analysis. All animal experiments were approved by Zurich Canton’s 
Veterinary office (approval number 151/2012). 
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2.2. Cell culture  
Human pulmonary artery smooth muscle cells (HPASMC) and human pulmonary artery 
endothelial cells (HPAEC) were obtained from Gibco (Life Technologies, Zug, Switzerland) 
and were cultured in supplemented medium 231 and supplemented medium 200 (both from 
Gibco), respectively. Human embryonic kidney (HEK)293 cells were grown in Dulbecco’s 
Modified Eagle Medium/Ham’s F-12 (DMEM/F12, Gibco) supplemented with 10% fetal calf 
serum, 10U/ml penicillin, 10µg/ml streptomycin, and 10mM HEPES (all reagents provided by 
Gibco). Human cells were cultured at 37°C in a humidified atmosphere of 5% CO2. For 
experiments in a hypoxic environment, HPASMC and HPAEC were cultured in a humidified 
atmosphere of 1% O2.  
 
2.3. Anti-miRs and LNA seed blockers design 
Antisense oligonucleotides (anti-miRs) targeting human miR-130a or human miR-301a were 
synthesized at Microsynth (Microsynth, Balgach, Switzerland). Increased RNA stability was 
achieved by methylation of its free 2’-hydroxy-group and by introducing six phosphothioate 
linkages as described by Krutzfeld et al. 15. The sequences are the following: anti-miR-130a 
(5’ – ASUSG CCC UUU UAA CAU UGC ASCSUS GS – 3’), anti-miR-301a (5’ – GSCSU UUG 
ACA AUA CUA UUG CASCS UsGs – 3’) and as a negative control anti-miR scrambled (5’ – 
GSASC CGU UCA CUA UUA CGA GUSCS ASAS – 3’). For inhibition of the entire miRNA 
family miR-130, seed blockers comprising the reverse complementary sequence of the 
miRNA seed match were designed 16. Efficient binding of these short oligonucleotides 
(octamers) to their corresponding miRNAs was achieved by using the locked nucleic acid 
(LNA) design. LNA seed blockers were obtained from Exiqon (Exiqon, Vedbaek, Denmark). 
The following LNA sequences were used:  LNA anti-miR-130 (5’ – AUU GCA CU – 3’) and 
as a negative control LNA scrambled (5’ – TCA TAC TA – 3’) as provided in Figure A.6. 
 
2.4. Quantitative real time-PCR (qPCR) analysis 
Total RNA of cultured cells or murine lung tissue samples was purified using the miRNeasy 
kit (Qiagen AG, Hombrechtikon, Switzerland). Isolated RNA was reverse transcribed by 
using random hexamers and MultiScribe reverse transcriptase (both from Life 
Technologies). Quantification of specific gene transcripts was performed by SYBR Green 
qPCR (Applied Biosystem 7500 system, Life Technologies). Sequences of primers used in 
this study are shown in the table A.1. Specific amplification was verified by performing melt 
curve analysis. Obtained expression levels of genes of interest were normalized to the 
expression of β-actin. Differential gene expression was calculated with the threshold cycle 
(Ct) method 17. 
Quantification of mature microRNAs 
Total RNA including miRNA fraction was extracted as described above. Mature miRNAs 
were detected by specific stem-loop primers, reverse transcribed using MultiScribe reverse 
transcriptase and quantified by performing SYBR Green qPCR 18. Primers used in this study 
for reverse transcription and amplification of miRNAs are provided in the table A.1. Obtained 
signals were normalized to the expression of snoRNA202 (murine control), RNU48 or 
RNU49 (both human controls). Specific amplification was confirmed by performing melt 
curve analysis.  
 
2.5. Western blot 
For protein extraction, harvested cells and murine lung tissue samples were lysed with 
sample loading buffer (62.5mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 5mM β-
mercaptoethanol, bromphenolblue). Whole-cell lysates were separated by sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and the proteins were transferred 
to nitrocellulose membrane (Whatman, GE Healthcare Life Sciences, Little Chalfont, UK). 
Membranes were incubated with the following primary antibodies: anti – CDKN1A (samples 
of human origin: rabbit antibody, #2947, Cell Signaling Technology, Danvers, MA, USA; 
samples of mouse origin: mouse antibody, sc-6246, Santa Cruz Biotechnology, Inc., Dallas, 
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TX, USA), and anti – β-actin (mouse antibody, #A2228, Sigma-Aldrich Chemie GmbH). 
Bands were detected with species-specific secondary antibodies coupled to horseradish 
peroxidase (Jackson ImmunoResearch Europe Ltd, Suffolk, UK). Calculation of the 
expression of proteins was performed using Adobe Photoshop CS5.1 software (Adobe 
Systems Incorporated, San Jose, CA, USA) via pixel quantification of the electronic image. 
 
2.6. Plasmid construction 
To verify a direct interaction between miRNAs and their predicted targets, the 3’ untranslated 
region (UTR) of the gene of human CDKN1A (1560bp) was amplified from human genomic 
DNA (Promega AG, Dübendorf, Switzerland) using conventional PCR. The obtained PCR 
product was double-digested with XbaI and SalI (all restriction enzymes from New England 
Biolabs, Ipswich, MA, USA) and cloned into the luciferase expressing pmiRGLO vector 
(Promega). In addition to the wildtype (WT) sequences, the predicted miR-130 binding site 
located in the 3’UTR of CDKN1A and was mutated by site-directed mutagenesis PCR as 
described in 19. Primer sequences used for cloning and mutagenesis are shown in table A.1. 
The correct sequence of the insert was confirmed by sequencing. 
 
2.7. Reporter gene assay 
HEK293 cells were seeded in 12-well plates at a density of 50.000 cells per well. The next 
day, cells were transfected with 200ng of pmiRGLO (either CDKN1A_WT or 
CDKN1A_ΔmiR130) using Lipofectamine 2000 (Life Technologies). Moreover, molecules for 
inhibition (anti-miRs or LNA seed blockers) or overexpression (pre-miRs, Life Technologies) 
of miR-130a or miR-301a (with a final concentration of 25nM) were added. After 24h, the 
cells were lysed, and Firefly luciferase activity was measured using the Dual-Luciferase 
Reporter Assay System (Promega). The values obtained were normalized to the activity of 
Renilla luciferase.  
 
2.8. Transient transfection of HPASMC 
For manipulation of endogenous levels of miR-130, HPASMC were transfected with pre-miR 
or LNA seed blocker (each 25nM) using Lipofectamine 2000. Silencing of the expression of 
CDKN1A was achieved by transfecting HPASMC with small interfering RNA (siRNA, 25nM) 
targeting the coding sequence of CDKN1A (validated siRNA from Qiagen, SI00299810) 
using Lipofectamine 2000. AllStars negative control siRNA (Qiagen) served as scrambled 
negative control. Following an incubation period of 24h, 48h or 72h cells were harvested and 
gene expression analysis was performed.  
 
2.9. Proliferation and apoptosis assay 
To assess the proliferation rate, HPASMC were seeded in 96-well plates at a density of 5000 
cells per well and were transfected with pre-miRs, anti-miRs or LNA seed blockers (all for 
the manipulation of the endogenous expression of the miRNA family miR-130, 25nM) using 
Lipofectamine 2000. After 48h, 5-bromo-2-deoxy-uridine (BrdU) was added and incubated 
for 24h. Incorporation of BrdU was detected using the colorimetric BrdU assay from Roche 
(Roche Diagnostics, Mannheim, Germany) and spectrophotometrically measured at a test 
wavelength of 450nm (reference wavelength: 630nm). The measured absorbance directly 
correlates with the proliferation and the number of cells. Cell viability was tested using the 
MTT-based CellTiter assay (Promega) according the manufacture’s protocol. Apoptosis was 
assessed by measuring the activity of caspase 3 and 7 (Caspase-Glo 3/7 assay, Promega). 
 
2.10. Statistics 
For statistical analysis, GraphPad Prism Software (GraphPad Software, San Diego, CA, 
USA) was used. Parametric or non-parametric distribution of data was determined using the 
Kolmogorov-Smirnov test. The paired or unpaired t-test (two-tailed) as a parametric method 
for testing was applied. For comparing of more than two sample groups the one-way 
analysis of variance with Bonferroni post hoc test (parametric distribution of data) or Kruskal-
Wallis test with Dunns post hoc test (non-parametric distribution of data) was used. Values 
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of p<0.05 were considered to be statistically significant (*p<0.05, **p<0.01, ***p<0.001). All 
data are shown as mean ± SD. 
 
3. Results 
 
3.1. The miR-130 family is induced by hypoxia 
Computational screening (www.targetscan.org 20) for miRNAs that target the 3’UTR of 
CDKN1A retrieved several miRNAs, of which the functionally related miR-130a/b and miR-
301a/b were, at least in terms of therapeutic approaches, found most interesting since this 
family of four different miRNAs might potentially be targeted by one single LNA seed 
blocker 16. These four miRNAs were then tested in an experimental model for PH (Fig. 1): 
upon exposure to hypoxia, mice developed PH as indicated by planimetric increase of the 
right ventricular volume (Fig. 1a). In lung tissue obtained from these mice, miR-130a 
(2.61±0.35 vs. 3±0.17, p=0.02, lower Ct values indicate higher expression of the miRNA of 
interest, Fig. 1b), miR-130b (7.93±0.45 vs. 8.37±0.48, p=ns, Fig. 1c), miR-301a (7.91±0.18 
vs. 8.2±0.19, p<0.01, Fig. 1d) and miR-301b (8.16±0.2 vs. 8.73±0.21, p<0.001, Fig. 1e) were 
significantly upregulated when compared to normoxic control animals. Kinetics of miR-130a 
expression and concomitant hemodynamic measurement after 2, 3 and 5 weeks are shown 
in Appendix Figure A.1.   
These data were confirmed in vitro by using HPASMC, which, under hypoxic conditions (1% 
O2 for up to 72h), showed a time-dependent trend toward upregulation of miR-130a and 
significant upregulation of miR-301a after 72h (1.56±0.19 fold change, p<0.01, Fig. A.2a) as 
compared to normoxic controls. No change of the expression levels was observed in human 
pulmonary artery endothelial cells (HPAEC, Fig. A.2b). These data suggest that HPASMC 
are the main source for overexpressed miR-130 family within the lungs. 
 
3.2. Transfection of miR-130a and miR-301a increases proliferation of HPASMC 
In a next step, HPASMC were transfected with two representative miRNAs derived from the 
miR-130 family, i.e. pre-miR molecules for miR-130a, miR-301a and a combination of both 
and proliferation was assessed using the BrdU incorporation assay. As shown in Figure 2a, 
overexpression of miR-130a increased proliferation of HPASMC as compared to scrambled 
transfected cells (in absorbance units at 450nm: from 0.43±0.2 to 0.62±0.2, p=0.06). 
Similarly, transfection of HPASMC with pre-miR-301a resulted in enhanced proliferation 
(from 0.43±0.2 to 0.75±0.24, p<0.01). A “cocktail” transfection using both pre-miRs had no 
additive effect but resulted in significant increase of proliferation as compared to scrambled 
transfected cells (from 0.43±0.2 to 0.66±0.19, p=0.043). Proliferation data were confirmed by 
using the MTT-based cell viability assay (Fig. A.3a). No effects were seen on apoptosis (Fig. 
A.3b).  
Conversely, inhibition of miR-130 family reduced proliferation of HPASMC significantly. Anti-
miRs specifically directed against miR-130a (from 0.68±0.3 to 0.37±0.24, p<0.01), miR-301a 
(from 0.68±0.3 to 0.25±0.2, p<0.001) or concomitant use of both anti-miRs (from 0.68±0.3 to 
0.25±0.15, p<0.01) decreased proliferation significantly (Fig. 2b). This effect was found to be 
enhanced by the use of LNA_anti-miR-130 (a seed blocker directed against the seed 
sequence of miR-130 that blocks all members of the miR-130 family) resulting in decreased 
proliferation from 0.48±0.24 to 0.17±0.07 (p<0.01, Fig. 2c).  
 
3.3. Members of the miR-130 family regulate the expression of CDKN1A 
Since CDKN1A is a major regulator of the cell cycle involved in proliferation 21, the 
expression of CDKN1A was investigated in HPASMC. In HPASMC, the transfection of pre-
miRs significantly decreased the expression of CDKN1A, both on mRNA and protein levels 
(Fig. 3a and 3b). In detail, transfection of pre-miR-130a caused a decrease on mRNA 
(0.71±0.07 fold change, p<0.01) and on protein levels (ratio to β-Actin: from 0.91±0.15 to 
0.66±0.16, p=0.027) as compared to scrambled controls. Overexpression of pre-miR-301a 
reduced the levels of CDKN1A by 0.61±0.08 fold change (p<0.01) on mRNA and from 
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0.91±0.15 to 0.65±0.2 (p=0.049) on protein levels. A “cocktail” transfection had no additive 
effect but resulted in significant decrease of mRNA levels of CDKN1A.  
Conversely, the use of LNA seed blockers directed against miR-130 increased the 
expression of CDKN1A significantly as compared to untreated controls, an effect observed 
both on mRNA and protein levels: LNA seed blocker directed against miR-130 increased the 
expression of CDKN1A by 1.46±0.22 fold (p=0.024) on mRNA level (Fig. 3c) and from 
0.62±0.19 to 1.07±0.18 (p<0.01) on protein level (Fig. 3d). Successful alteration of miR-130 
expression in HPASMC was proven by qPCR analysis and is provided in Figure A.4.  
Reporter gene constructs of the entire 3’UTR of CDKN1A (Fig. 4a) were employed to 
investigate whether the interaction between miR-130a and miR-301a and CDKN1A is direct 
or indirect. In the wild-type construct, addition of miR-130a (0.84±0.09 fold change, p<0.01) 
and miR-301a (0.85±0.17 fold change, p=0.045) resulted in significant reduction of relative 
luciferase activity, whereas insertion of specific point mutations in the miR-130 seed match 
of CDKN1A abolished the miRNA-induced reduction of luciferase activity (Fig. 4b). Vice 
versa, treatment with LNA seed blockers increased the relative luciferase activity of the wild-
type construct by 1.12 fold change (p<0.01) when compared to scrambled controls. No 
effects on the luciferase activity were observed in the mutated construct (Fig. 4c).  
 
3.4. Silencing of CDKN1A by siRNA mimics the effects of miR-130a and miR-301a 
As a proof of principle, siRNA targeting the mRNA of CDKN1A (si_CDKN1A) was performed. 
As shown in Figure 5a and 5b, expression of CDKN1A was significantly reduced on mRNA 
(0.42±0.07 fold change, p<0.001) and protein levels (from 1.23±0.13 to 0.64±0.07, p<0.001) 
when cells were treated with si_CDKN1A. Proliferation of HPASMC was found to be 
significantly increased when assessed by the BrdU incorporation assay in cells treated with 
si_CDKN1A compared to scrambled negative control (from 0.47±0.24 to 0.66±0.3, p=0.042, 
Fig. 5c). 
 
3.5. Hypoxia reduces the expression of CDKN1A in vitro and in vivo 
The effects of hypoxia on the expression of CDKN1A were tested in vitro by using HPASMC 
and in vivo in lung tissue obtained from mice that were kept for 3 weeks under hypoxic 
conditions (10% O2) and developed PH. Levels of CDKN1A mRNA in HPASMC were found 
to be significantly reduced at different time points from 8h (by 0.69±0.05 fold change, 
p<0.01) to 72h (by 0.77±0.08 fold change, p<0.01, Fig. A.5a). These findings were confirmed 
in vivo showing decreased mRNA levels of CDKN1A (by 0.81±0.2 fold change, p=0.03, Fig. 
A.5b) in hypoxic mice when compared to normoxic control animals. 
 
3.6. LNA seed blockers against miR-130 restore the expression of CDKN1A and ameliorate 
right ventricular hypertrophy  
The therapeutical effects of inhibiting miR-130 were investigated by the use of LNA seed 
blockers, which were injected intraperitoneally twice in hypoxic animals (Fig. 6a). Planimetric 
analysis of the ratio between the right and left ventricular volume (Fig. 6b) showed that the 
differences between normoxic controls (0.25±0.04) and hypoxic animals (LNA scrambled, 
0.40±0.07) were no longer significant after treatment with LNA seed blockers (0.35±0.04) 
indicating an improvement of right ventricular hypertrophy. The expression of CDKN1A was 
found significantly increased in lung tissue after injections of LNA 130 (Fig. 6c).  
 
4. Discussion 
 
Herein we showed that major members of the miRNA family miR-130 are upregulated in the 
murine model of hypoxia-induced PH, that, upon induction by hypoxia, regulate proliferation 
in HPASMC by directly targeting the tumor suppressor CDKN1A (p21). In addition, we 
demonstrated that a novel generation of miRNA-inhibiting compounds, i.e. LNA seed 
blockers, are a feasible approach to efficiently counteract the activity of the miR-130 family. 
These data imply an important role of miR-130 in the pathogenesis of pulmonary vascular 
remodeling, which, to date, remains an untreated condition. 
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Proliferation of HPASMC is an essential feature that triggers the development of vascular 
remodeling, which, itself, is the most important factor in the pathogenesis of PH. The factors 
that induce a pro-proliferative phenotype in these cells are not completely understood.  
 
The most important factor identified in remodeling of pulmonary arteries is BMPR2, which, 
when mutated or dysregulated, results in a pro-proliferative state of endothelial and smooth 
muscle cells. miRNAs of the cluster miR-17/92 have been implicated to silence BMPR2 11, 22. 
Since miRNAs act in a pleiotropic manner, i.e. one specific miRNA might have many gene 
targets whereas one gene might be targeted by many different miRNAs, we tested whether 
miR-130 binds the 3’UTR of BMPR2. Although predicted by software, miR-130a and miR-
301a appeared to have no direct effects on the expression of BMPR2 in HPASMC (data not 
shown). 
 
Hypoxic conditions due to pulmonary disorders result in the elevation of the pulmonary 
pressure and are used to mimic human disease in experimental models. Hypoxia induces 
proliferation of vascular smooth muscle cells, probably mediated by downregulation of 
CDKN1A 23. In another study, this pro-proliferative and anti-senescent effect was enhanced 
in animals lacking CDKN1A 4. Since miRNAs are an emerging group of factors that regulate 
gene expression, we performed an in silico approach to identify miRNAs that potentially 
target CDKN1A. Several miRNAs were retrieved and tested, among which four members of 
the miR-130 family were found to be induced by hypoxia in lung tissue and HPASMC. Of 
interest, a very recent study has elegantly shown that the miR-130 family heads a network of 
miRNAs that regulates proliferation in PH 24. Our findings confirm these data and previous 
reports on miRNA analysis in experimental hypoxia-induced PH that found miR-130a/miR-
301a significantly upregulated 25. Moreover, miR-130 was already implicated in the 
proliferation of vascular smooth muscle cells in systemic hypertension 26 and was associated 
with the development of airways and lung vessels 27.  
 
Bertero et al. suggested a role of miR-130 for controlling the expression of CDKN1A 24. 
However, the question remained unanswered whether miR-130 itself or one of the 
subordinated miRNA pathways affects this master regulator of proliferation. Moreover, it was 
unclear whether the effects observed were the consequence of a direct miRNA-mediated 
interaction or whether other factors are involved. Our data here, employing reporter gene 
studies with constructs of the 3’UTR of CDKN1A (wildtype and mutated miR-130 seed 
match) identified a direct interaction of miR-130 family with the transcript of CDKN1A. These 
findings highlight the importance of miR-130 in pulmonary vascular remodeling and have 
further impacts for our understanding of the pathogenesis of the disease and the 
development of causative therapies. The most commonly described pathway that regulates 
the expression of CDKN1A involves the tumor suppressor p53, probably activated by the 
hypoxia-induced factor 1 alpha (Hif-1α), that acts upstream of CDKN1A 28, 29. In these 
studies, however, hypoxia resulted in upregulation of CDKN1A and, in turn, cell cycle arrest. 
In contrast to these findings, our data emphasize an alternative signaling mechanism 
involving the hypoxia-induced miR-130a and miR-301a that bind CDKN1A and suppress its 
expression independent of p53-responsive elements. The contradictory results in our and 
previous studies are not fully explained at this moment, but might, similar to the paradoxical 
vasoconstriction induced by hypoxia, represent a unique feature of pulmonary vessels. Since 
the p53 activator Nutlin-3a required the presence of CDKN1A to improve hemodynamics and 
prevention of remodeling in hypoxia-induced PH 4, we suggest that CDKN1A, rather than 
p53, is the critical factor that regulates proliferation of vascular smooth muscle cells in the 
development of pulmonary vascular remodeling.  
 
Inhibition of the miRNA family miR-130 was achieved by anti-miRs, that were conventionally 
designed directed against one single member of the miRNA family or by employing LNA 
seed blockers that have the potential to silence the whole family of miRNAs that share the 
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same seed region at once. In our experiments, the use of LNA seed blockers showed similar 
efficacy as anti-miRs. As discussed elsewhere 16, however, LNA seed blockers have the 
advantage of being active at low (nanomolar) doses and, although they lack tissue specificity 
and accumulate in many cells, they appear to have no significant side effects. After 
treatment of hypoxic animals with LNA seed blockers, differences in right heart hypertrophy 
and in the expression of CDKN1A in lung tissue were no longer significant between these 
mice and normoxic controls. These data highlight the therapeutic potential of LNA seed 
blockers to lower the expression of miR-130 in vivo and might offer a feasible approach to 
address proliferation and vascular remodeling in PH.  
 
Taken together, this is the first report emphasizing that the cell-cycle regulator CDKN1A is a 
direct target of the miRNA family miR-130, which, induced by hypoxia, might be involved in 
the development of vascular remodeling in PH. 
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Figure Legends 
 
Figure 1. miR-130 family members are increased in hypoxia-induced Pulmonary 
Hypertension. (a) In hypoxic animals, the planimetric ratio between the right and left 
ventricle size including septum indicated right ventricular hypertrophy and was found to be 
significantly higher than in normoxic controls. The expression levels of miR-130a (b), miR-
130b (c), miR-301a (d), and miR-301b (e) were found to be increased in lung tissue of 
hypoxia-treated mice (10% O2 for 3 weeks) when compared to normoxic controls. A lower Ct 
value indicates a higher expression level of the miRNA of interest. Statistical analysis by 
unpaired Student’s t-test (*p<0.05, **p<0.01, ***p<0.001) 
 
Figure 2. The miR-130 family regulates the proliferation of human pulmonary artery 
smooth muscle cells (HPASMC). (a) HPASMC transfected with precursor molecules for 
miR-130a (pre-miR-130a), miR-301a (pre-miR-301a) and a cocktail of both showed higher 
proliferation rates when compared to scrambled transfection (n≥6). (c) In contrast, the 
inhibition of miRNAs by treatment with individual antisense molecules (anti-miRs) resulted in 
lower proliferation rates (n≥6). (c) The simultaneous inhibition of all members of the miR-130 
family by transfection of LNA seed blockers (LNA anti-miR-130) significantly decreased the 
proliferation of HPASMC when compared to scrambled negative control (n=9). Statistical 
analysis by unpaired Student’s t-test (*p<0.05, **p<0.01, ***p<0.001). 
 
Figure 3. The tumour suppressor p21 (CDKN1A) is targeted by members of the miR-
130 family in human pulmonary artery smooth muscle cells. Enforced expression of 
miR-130a and miR-301a by transfection with the respective pre-miRs resulted in 
downregulation of mRNA (a) and protein (b) levels of CDKN1A (n≥4). Conversely, the 
simultaneous inhibition of all members of the miR-130 family using LNA anti-miR-130 led to 
upregulation of CDKN1A on the level of mRNA (c) and protein (d) when compared to cells 
transfected with scrambled negative control (n≥4). Statistical analysis by unpaired (b and d) 
and paired (a and c) student’s t-test (*p<0.05, **p<0.01). The negative control (scrambled) 
was arbitrarily set as 1 (a and c).  
 
Figure 4. Reporter gene assay confirms a direct and specific regulation of CDKN1A by 
the miR-130 family. (a) The entire 3’UTR of CDKN1A comprising one miR-130 binding site 
(seed match) was cloned into a dual luciferase-expressing vector. The pairing of RNA as 
predicted by TargetScan (www.targetscan.org) between miR-130a and the 3’UTR of 
CDKN1A (CDKN1A_WT) is shown. In addition, the predicted miR-130 seed match was 
deleted by introducing three point mutations (construct CDKN1A_ΔmiR130). (b) Reporter 
gene studies showed that co-transfection of miR-130a and miR-301a significantly lowered 
the relative luciferase activity of CDKN1A_WT as compared to scrambled transfection (n≥7). 
The mutated construct was not affected by overexpression of miR-130a and miR-301a 
(n=4). (c) Conversely, treatment with LNA anti-miR-130 significantly increased the relative 
luciferase activity of the CDKN1A_WT, whereas no effects on the luciferase activity were 
observed in the mutated construct (n=5). Statistical analysis by paired Student’s t-test 
(*p<0.05, **p<0.01). 
 
Figure 5. Specific silencing of CDKN1A increases proliferation of human pulmonary 
artery smooth muscle cells (HPASMC). The expression of CDKN1A was specifically 
decreased by transfecting HPASMC with gene-specific siRNA (si_CDKN1A). Knockdown of 
the expression of CDKN1A was confirmed on mRNA (a) and protein level (b) (each n=4). (c) 
The proliferation of HPASMC was found to be enhanced upon transfection with si_CDKN1A 
as assessed by BrdU incorporation assay (n≥8). Statistical analysis by paired (a) and 
unpaired Student’s t-test (b and c) (*p<0.05, ***p<0.001). The negative control (scrambled) 
was arbitrarily set as 1 (a). 
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Figure 6. Inhibition of the miR-130 family by LNA seed blockers restores the 
expression of CDKN1A and ameliorates right ventricular hypertrophy in mice. The 
hypoxia-induced Pulmonary Hypertension mouse model was used to investigate the 
therapeutical effects of LNA seed blockers. (a) Male mice were randomly separated to 
receive normoxia saline (n=8), hypoxia saline (n=8), hypoxia LNA scrambled (LNA scr, n=7), 
and hypoxia LNA anti-miR-130 (LNA 130, n=7). After 21 and 28 days of hypoxia (10% O2) 
saline, LNA scr, and LNA 130 (both 2.5mg/kg bodyweight) were intraperitoneally injected. 
Mice were sacrificed at day 35. (b) The planimetric ratio of the right to left ventricular size 
was found significantly increased in the hypoxic control group (saline and LNA scr) when 
compared to normoxic mice. These differences were no longer significant after treatment 
with LNA 130 indicating an improvement of right ventricular hypertrophy in these mice. 
Figure bar in tissue slides indicates 1mm. (c) The expression of CDKN1A was measured in 
lung tissue by western blot. Hypoxic conditions significantly decreased the protein levels of 
CDKN1A in the saline group when compared to normoxic control mice. Conversely, 
injections of LNA 130 significantly upregulated the expression of CDKN1A when compared 
to hypoxic control mice demonstrating the beneficial effect of LNA 130 on the expression of 
CDKN1A. Statistical analysis by Kruskal-Wallis test with Dunns post hoc test (*p<0.05, 
**p<0.01, ***p<0.001). 
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The hypoxia-induced microRNA-130a controls pulmonary smooth muscle cell 
proliferation by directly targeting CDKN1A. 
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Table A.1. Primer sequences 
 
miRNA expression primer  
miR-130a/b RT 5’ - GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC 
GCA GAT CTG ACG ACA TGC CC - 3’ 
miR-130a fwd (hsa, mmu) 5’ - CTG CAG TGC AAT GTT AAA AGG - 3’ 
miR-130b fwd (hsa, mmu) 5’ – CAG CAG TGC AAT GAT GAA AGG – 3’ 
miR-301a/b RT 5’ - GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC 
GCA CTG GAT ACG ACG CTT TG - 3’  
miR-301a fwd (hsa, mmu) 5’ - CCA GTG CAA TAG TAT TGT CAA AG - 3’ 
miR-301b fwd (hsa) 5’ - GGA GTG CAA TGA TAT TGT CAA AG - 3’ 
miR-301b fwd (mmu) 5’ - GGA GTG CAA TGG TAT TGT CAA AG - 3’ 
snoRNA202 RT 5’ – GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC 
GCA CTG GAT ACG ACC ATC AG – 3’ 
snoRNA202 (mmu) fwd 5’ – CCG TAC TTT TGA ACC CTT TTC – 3’ 
RNU48 RT 5’ – GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC 
GCA CTG GAT ACG ACG GTC AG – 3’ 
RNU48 (hsa) fwd 5’ – CCA TGA GTG TGT CGC TGA TG – 3’ 
RNU49 RT 5’ – GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC 
GCA CTG GAT ACG ACA ATC AG – 3’ 
RNU49 (hsa) fwd 5’ – AAG CGA TAA CTG ACG AAG ACT AC – 3’ 
universal reverse primer 5’ - GAG GTA TTC GCA CTG GAT AC - 3’ 
gene expression primer  
β-actin (hsa, mmu) fwd 5’ – TCA AGA TCA TTG CTC CTC CTG AG – 3’ 
β-actin (hsa, mmu) rev 5’ – TCC TGC TTG CTG ATC CAC ATC – 3’ 
CDKN1A (mmu) fwd 5’ - AGC CTG ACA GAT TTC TAT CAC TC – 3’ 
CDKN1A (mmu) rev 5’ - AGG GTT TTC TCT TGC AGA AGA C – 3’ 
CDKN1A (hsa) fwd 5’ - AGC ATG ACA GAT TTC TAC CAC TC – 3’ 
CDKN1A (hsa) rev 5’ - GGC TTC CTC TTG GAG AAG ATC – 3’ 
cloning primer  
3’UTR of CDKN1A (XbaI) fwd  5’ - CGA GTC TAG ATC CGC CCA CAG GAA GC – 3’ 
3’UTR of CDKN1A (SalI) rev  5’ - CCT GCA GGT CGA CAC AAG TAA AGT CAC TAA 
GAA TC – 3’ 
3’UTR of CDKN1A (ΔmiR-
130) fwd  
5’ – ATT GCC AGT TGA TTA GCA GCG – 3’ 
3’UTR of CDKN1A (ΔmiR-
130) rev 
5’ – ATC AAC TGG CAA TGA ACT GGG – 3’   
 
  
Appendix Figure Legends 
 
Figure A. 1. Kinetics of miR-130a expression in vivo. Expression levels of miR-130a in 
lung tissue from mice exposed to 10% oxygen for 2 (n=3), 3 (n=8) and 5 (n=8) weeks are 
shown. Concomitant invasive hemodynamic measurement (right ventricular systolic 
pressure, RSVP) and planimetric assessment of volume changes of the right ventricle are 
provided below. Statistical analysis by unpaired Student’s t-test (*p<0.05). 
 
Figure A. 2. Hypoxia induces the expression of miR-130a and miR-301a in human 
pulmonary artery smooth muscle cells (HPASMC). (a) HPASMC cultured in hypoxic 
conditions showed higher expression of miR-130a and miR-301a in a time-dependent 
manner when compared to normoxic cells (n=4). (b) Hypoxia had no effect on the expression 
of miR-130 family members in human pulmonary artery endothelial cells (n=5). Statistical 
analysis by paired Student’s t-test (**p<0.01). The dashed line indicates the expression 
levels of normoxic control cells, which was arbitrarily set as 1. 
 
Figure A. 3. Viability and apoptosis assay. (a) Viability of HPASMC following 
overexpression of miR-130, miR-301a and a cocktail of both was tested by using the MTT-
based CellTiter assay and showed a significant increase of cell viability in miR-301a and 
cocktail transfected cells (n=4). (b) Conversely, no effects were observed on apoptosis of 
HPASMC after overexpression of miR-130a, miR-301a and a cocktail of both as analysed by 
the activity of caspase 3/ 7 (n=4). Statistical analysis by unpaired Student’s t-test (*p<0.05). 
 
Figure A. 4. Confirmation of successful transfection of the miR-130 family in human 
pulmonary artery smooth muscle cells (HPASMC). (a) The expression of miR-130a was 
significantly increased upon transfection of HPASMC with pre-miR as measured by qPCR 
(n=4). (b) In contrast, the levels of miR-130a did not change when LNA seed blockers (LNA 
anti-miR-130) were transfected (n=4). Seed blockers sequestrate their target miRNA by 
forming a heteroduplex structure whereas the stability of the miRNA is not affected 1. Similar 
results were obtained when the expression of miR-301a was measured in pre-miR (c) or in 
LNA anti-miR-130 (d) transfected HPASMC (n=4). **p<0.01, ***p<0.001 by paired Student’s 
t-test. The negative control (scrambled) was arbitrarily set as 1. 
 
Figure A. 5. The expression of CDKN1A is repressed by hypoxia in vitro and in vivo. 
(a) Levels of CDKN1A mRNA in human pulmonary artery smooth muscle cells kept under 
hypoxic conditions (1% O2) were found to be significantly decreased at different time points 
(n=4). (b) Similarly, mRNA levels of CDKN1A in hypoxic mice (3 weeks at 10% O2, n=8) 
were significantly lower when compared to normoxic control animals (n=7). *p<0.05, 
**p<0.01 by paired Student’s t-test. The dashed line indicates the expression levels of 
normoxic control cells, which was arbitrarily set as 1 (a). 
 
Figure A. 6. Design of seed blockers directed against the seed sequence of the miR-
130 family. The sequence of four members of the miR-130 family (miR-130a, miR-130b, 
miR-301a, miR-301b) is shown. The LNA seed blockers were specifically designed to bind to 
the seed region of miR-130, a sequence motif shared by all members of the miRNA family. 
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Figure A.1 
Expression of 
miR-130a 
 
(x-fold change) 
RVSP  
(mmHg) 30.83 ± 2.6 45.5 ± 3.63 27 40.5 
RV/ (LV+S)  
(mm2) 
0.25 ± 0.04 0.38 ± 0.11 0.16 ± 0.01 0.25 ± 0.02 - - 
- - 
Nx Hx Nx Hx Nx Hx 
3 weeks 2 weeks 5 weeks 
1.04 ± 0.35  1.18 ± 0.23  1 ± 0.11 1.21 ± 0.04 1.03 ± 0.15  1.29 ± 0.31 
a) 
b) 
Figure A.2 
Figure A.3 
a) b) 
Figure A.4 
a) b) 
c) d) 
Figure A.5 
a) b) 
Figure A.6 
miR-130a         5’ - CAG UGC AAU GUU AAA AGG GCA U - 3’ 
miR-130b         5’ - CAG UGC AAU GAU GAA AGG GCA U - 3’ 
miR-301a         5’ - CAG UGC AAU AGU AUU GUC AAA GC - 3’ 
miR-301b         5’ - CAG UGC AAU GAU AUU GUC AAA GC - 3’ 
Seed region:             AG UGC AAU 
Seed blocker:      3’ - UC ACG UUA - 5’      
       
miRNA family miR-130 
